Crinetics Pharmaceuticals (CRNX) Operating Leases (2019 - 2026)

Crinetics Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $41.3 million for Q1 2026.

• On a quarterly basis, Operating Leases fell 5.96% year-over-year to $41.3 million in Q1 2026; TTM through Mar 2026 was $41.3 million, a 5.96% decrease from a year earlier, with the FY2025 full-year figure at $42.1 million, down 5.65% from the prior year.
• Operating Leases eased to $41.3 million in Q1 2026 per CRNX's latest filing, from $42.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $48.2 million in Q3 2023 and bottomed at $1.5 million in Q2 2023.
• The 5-year median for Operating Leases is $42.7 million (2025), against an average of $29.7 million.
• Across the five-year window, Operating Leases sank 43.24% in 2023 and jumped 3050.62% in 2024, its largest moves.
• Year by year, Operating Leases stood at $2.0 million in 2022, then soared by 2249.56% to $47.6 million in 2023, then slipped by 6.28% to $44.6 million in 2024, then dropped by 5.65% to $42.1 million in 2025, then retreated by 1.74% to $41.3 million in 2026.
• Per Business Quant, the three latest CRNX Operating Leases figures stand at $41.3 million (Q1 2026), $42.1 million (Q4 2025), and $42.7 million (Q3 2025).